This trial will compare the effectiveness of a combination of pembrolizumab and BCG to BCG monotherapy in treating people with high-risk, non-muscle invasive bladder cancer.
2 Primary · 18 Secondary · Reporting Duration: Up to ~3.5 years
Experimental Treatment
1405 Total Participants · 5 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: